If you have polycystic ovary syndrome (PCOS) and you've been researching GLP-1 medications, you've probably run into a wall: most information frames these drugs as treatments for type 2 diabetes and obesity. But you do not need a diabetes diagnosis to be prescribed a GLP-1 medication — and for many patients with PCOS, these medications address the core metabolic driver of the condition.
This guide explains who qualifies, how the eligibility criteria actually work, what documentation helps your case, and how to find a telehealth provider who understands PCOS.
Why GLP-1 Medications Are Relevant to PCOS
PCOS is primarily a hormonal disorder, but its metabolic dimension is what makes GLP-1 drugs clinically relevant. Up to 70–80% of women with PCOS have insulin resistance — even women who are not overweight.
The insulin resistance connection matters for two reasons. First, high insulin levels directly stimulate the ovaries to produce more androgens (male hormones), which disrupts ovulation and drives the hormonal cascade that defines PCOS. Treating insulin resistance can interrupt this cycle. Second, GLP-1 medications work partly by improving insulin sensitivity and reducing fasting insulin levels — the same pathway that metformin targets, but through a different mechanism and typically with greater efficacy for weight reduction.
The question most patients with PCOS ask isn't whether these drugs could help — it's whether they can actually get access to them without diabetes. The answer is yes, and the pathway is more accessible than most patients realize.
FDA Approval Status: What It Actually Means for You
GLP-1 medications do not have FDA approval for PCOS. Here is what is actually approved:
| Medication | FDA-Approved Indication |
|---|---|
| Ozempic (semaglutide 0.5–2.0mg weekly) | Type 2 diabetes |
| Mounjaro (tirzepatide 2.5–15mg weekly) | Type 2 diabetes |
| Wegovy (semaglutide 2.4mg weekly) | Chronic weight management (BMI ≥30, or ≥27 + comorbidity) |
| Zepbound (tirzepatide 2.5–15mg weekly) | Chronic weight management (BMI ≥30, or ≥27 + comorbidity) |
Prescribing an approved medication for a use outside its label — "off-label prescribing" — is legal and common in American medicine. Physicians prescribe off-label roughly 20% of the time. For PCOS specifically, off-label prescribing is the norm: metformin is the most-prescribed drug for PCOS and has no PCOS-specific FDA indication.
Who Qualifies: The BMI and Comorbidity Criteria
Most telehealth platforms and clinicians evaluating patients for GLP-1 therapy use the same criteria that govern the weight management indications: BMI ≥30, or BMI ≥27 plus at least one weight-related comorbidity.
PCOS with insulin resistance is widely recognized by endocrinologists and GLP-1 telehealth providers as a qualifying comorbidity. Other comorbidities that frequently accompany PCOS — hypertension, dyslipidemia, prediabetes, sleep apnea — also qualify independently.
Practical implications:
-
BMI ≥30: You will likely qualify for a weight management indication (Wegovy/Zepbound) without needing to document PCOS specifically. The PCOS context remains clinically relevant for treatment goals.
-
BMI 27–29.9 with PCOS: You should document your PCOS diagnosis and, if available, metabolic markers such as elevated fasting insulin, elevated HOMA-IR, or other signs of insulin resistance. This strengthens the clinical rationale for off-label prescribing.
-
BMI below 27 with PCOS: This is the most challenging category. Some providers will prescribe off-label based on documented insulin resistance and PCOS, but fewer telehealth platforms have standardized pathways for this group. A reproductive endocrinologist or OB/GYN with metabolic medicine experience may be better suited than a general GLP-1 telehealth platform.
What Documentation Helps Your Case
When you consult a telehealth provider about GLP-1 therapy for PCOS, these records help establish medical necessity and clinical rationale:
Diagnosis documentation:
- PCOS diagnosis in your medical records (primary care, OB/GYN, or endocrinologist)
- Ultrasound findings if available
- Prior lab work showing elevated androgens (testosterone, DHEA-S, SHBG)
Metabolic markers (most useful):
- Fasting insulin level
- HOMA-IR calculation (derived from fasting insulin and glucose)
- Fasting glucose
- HbA1c (especially if in prediabetic range)
- Lipid panel (dyslipidemia is common in PCOS and a qualifying comorbidity)
Prior treatment history:
- Metformin use, duration, and outcome
- Other insulin-sensitizing agents
- Hormonal contraceptive history (providers may want to understand your full clinical picture)
You don't need all of this. Presenting your PCOS diagnosis alongside documented insulin resistance and your current BMI is typically sufficient for most telehealth platforms to proceed.
How the Telehealth Intake Process Works
Most GLP-1 telehealth platforms use asynchronous or synchronous consult models where a provider reviews your intake questionnaire and medical history before prescribing.
When you apply, you will typically be asked about:
- Current BMI and weight history
- Diagnoses and comorbidities (list PCOS here explicitly)
- Diabetes history (you'll indicate no T2D diagnosis — this doesn't disqualify you)
- Prior weight loss treatment attempts
- Current medications
- Relevant medical history (thyroid disease, pancreatitis, MEN 2)
Indicate PCOS clearly, along with any metabolic markers you know. Some platforms will flag PCOS as an appropriate comorbidity for weight management prescribing; others may need the provider to recognize the clinical picture. If the platform's intake is too narrowly focused on diabetes or BMI-only qualification, that's a signal to look for a more clinically sophisticated provider.
What GLP-1 Therapy Can (and Can't) Do for PCOS
Managing expectations honestly matters here.
What the evidence supports:
- Significant weight reduction in PCOS patients who are overweight or obese — trials show meaningful reductions in body weight, waist circumference, and body fat distribution, which in turn reduces insulin load on the ovaries
- Improvements in insulin sensitivity — fasting insulin and HOMA-IR decrease in most patients on GLP-1 therapy
- Reduction in androgen levels — multiple studies report decreases in total and free testosterone in PCOS patients treated with GLP-1 medications, particularly when weight loss accompanies treatment
- Improvements in cycle regularity — observational data and case series report menstrual regularization in some patients, likely related to androgen reduction and weight loss
What remains uncertain:
- Whether GLP-1s improve fertility outcomes specifically — studies on ovulation rate and conception are limited, and the picture is complicated by weight loss effects
- Whether non-obese PCOS patients receive the same benefit as those with significant insulin resistance and weight to lose
- Long-term PCOS-specific outcomes — most trials are 6–12 months, not multi-year
For a detailed comparison of semaglutide vs tirzepatide specifically for PCOS, see our semaglutide vs tirzepatide PCOS guide.
Cost and Access
With insurance: Coverage for GLP-1s in PCOS without diabetes is unlikely through a PCOS-specific pathway. If you qualify under a weight management indication (Wegovy/Zepbound with BMI ≥27 + comorbidity), your insurer's obesity benefit may apply — but many plans still exclude weight management drugs. Check your formulary directly.
Through telehealth with compounded semaglutide: This is the primary access pathway for most PCOS patients paying out of pocket. Compounded semaglutide is available at $100–$450/month through 15+ telehealth platforms, compared to $1,300–$1,500/month for brand-name Wegovy. For PCOS patients who need long-term therapy — and most do — compounded options significantly change the affordability calculus.
See our GLP-1 provider comparison to find platforms that serve your state and offer GLP-1s at accessible price points.
A Note on PCOS-Specific vs General GLP-1 Platforms
Most GLP-1 telehealth platforms are optimized for obesity and metabolic weight loss — their intake forms, monitoring protocols, and prescribing frameworks are built around those use cases. For PCOS patients, this works reasonably well if BMI and comorbidity criteria are met.
However, PCOS involves hormonal complexities that go beyond metabolic health: cycle monitoring, fertility considerations, contraceptive interactions, and androgen-related symptoms. If you're pursuing GLP-1 therapy primarily for PCOS rather than weight loss, consider supplementing your telehealth GLP-1 provider with a reproductive endocrinologist or OB/GYN who can monitor the PCOS-specific outcomes you care about — androgen levels, cycle regularity, and any fertility goals.
Frequently Asked Questions
Can I get semaglutide or tirzepatide for PCOS if I don't have diabetes?
Yes. GLP-1 medications are prescribed for PCOS without a diabetes diagnosis through off-label use. Most telehealth platforms qualify patients based on BMI (≥30, or ≥27 with at least one comorbidity), not diabetes status. PCOS with insulin resistance is widely recognized as a qualifying comorbidity. You will need to document your PCOS diagnosis and, if BMI is below 30, relevant metabolic markers such as elevated fasting insulin or HOMA-IR.
Does GLP-1 therapy help PCOS symptoms beyond weight loss?
Research suggests GLP-1 medications can improve insulin resistance, reduce fasting glucose and insulin levels, and may lower elevated androgen levels — which can improve cycle regularity and reduce hirsutism. These improvements are partially independent of weight loss, suggesting a direct metabolic effect. However, GLP-1s are not FDA-approved for PCOS, and evidence on fertility outcomes and long-term cycle regularity is still emerging.
Which GLP-1 medication is best for PCOS without diabetes?
There is no FDA-approved GLP-1 for PCOS, so all use is off-label. Semaglutide has the most published evidence in PCOS populations. Tirzepatide is increasingly prescribed for PCOS given its dual GIP/GLP-1 mechanism and superior weight loss outcomes, but PCOS-specific clinical data remains limited. Your provider should assess your metabolic profile and clinical history to recommend one over the other.
Will insurance cover GLP-1 medications for PCOS without diabetes?
Probably not on the basis of PCOS alone. If your BMI and a qualifying comorbidity meet the weight management indication criteria, coverage under an obesity benefit may be possible. Otherwise, out-of-pocket options include compounded semaglutide at $100–$450/month through telehealth. Check your specific plan's formulary, as coverage continues to evolve rapidly.
Use the TeleHealthAlly provider comparison to find GLP-1 telehealth platforms in your state that offer compounded semaglutide at transparent pricing — without needing to sort through provider marketing to understand what you'll actually pay.